Lista de obras - Raphael A Itzykson - Dominio Público Uruguay

A landscape of germline mutations in a cohort of inherited bone marrow failure patients

artículo científico publicado en 2017

A multiparametric niche-like drug screening platform in acute myeloid leukemia

artículo científico publicado en 2022

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

artículo científico publicado en 2014

Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease

artículo científico publicado en 2014

Allogeneic hematopoietic cell transplantation following the use of hypomethylating agents among patients with relapsed or refractory AML: Findings from an international retrospective study.

artículo científico publicado en 2018

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

artículo científico publicado en 2015

An evolutionary perspective on chronic myelomonocytic leukemia.

artículo científico

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

artículo científico publicado en 2015

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

artículo científico publicado en 2015

Applying ecological and evolutionary theory to cancer: a long and winding road ⬇️

artículo científico publicado en 2012

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients

artículo científico publicado en 2014

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

artículo científico publicado en 2013

Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia

scientific article published on 20 March 2019

Bleeding in patients with Budd-Chiari syndrome

artículo científico publicado en 2010

CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease

artículo científico publicado en 2015

CMML: Clinical and molecular aspects.

artículo científico publicado en 2017

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

artículo científico publicado en 2015

Choosing a hypomethylating agent in MDS: does gender matter?

artículo científico publicado en 2017

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

artículo científico publicado en 2015

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

artículo científico publicado en 2015

Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?

artículo científico publicado en 2013

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

artículo científico publicado en 2017

Clonal architecture of chronic myelomonocytic leukemias

artículo científico publicado en 2013

Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy

artículo científico publicado en 2020

Clonal interference of signaling mutations holds prognostic relevance in core binding factor acute myeloid leukemia.

artículo científico publicado en 2018

Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML

artículo científico publicado en 2018

Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation

artículo científico publicado en 2014

Diagnosis of ureaplasma urealyticum septic polyarthritis by PCR assay and electrospray ionization mass spectrometry in a patient with acute lymphoblastic leukemia.

artículo científico publicado en 2014

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

scientific article published on 15 December 2011

Epigenetics of myelodysplastic syndromes

artículo científico publicado en 2013

Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia

article

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

artículo científico publicado en 2021

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

scholarly article by Ashfaq Ali et al published 26 February 2018 in Leukemia

Home spirometry in bronchiolitis obliterans after allogeneic haematopoietic cell transplant.

artículo científico publicado en 2018

How I treat chronic myelomonocytic leukemia

artículo científico publicado en 2017

How and when to decide between epigenetic therapy and chemotherapy in patients with AML.

artículo científico publicado en 2017

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

artículo científico publicado en 2018

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

artículo científico publicado en 2011

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases

artículo científico publicado en 2009

Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality

scientific article published on 30 July 2020

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.

artículo científico publicado en 2013

MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.

artículo científico publicado en 2012

Macrophage migration inhibitory factor is overproduced through EGR1 in TET2<sup>low</sup> resting monocytes

artículo científico publicado en 2022

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study

artículo científico publicado en 2020

Meeting report: myelodysplastic syndromes at ASH 2007.

artículo científico publicado en 2008

Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.

artículo científico publicado en 2014

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

artículo científico publicado en 2011

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

artículo científico publicado en 2016

Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia.

artículo científico publicado en 2013

Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

artículo científico publicado en 2018

Myelodysplastic syndromes

artículo científico publicado en 2014

New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.

artículo científico

Novel M-component based biomarkers in Waldenström's macroglobulinemia

artículo científico publicado en 2011

Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation.

artículo científico publicado en 2005

Optimal sequencing of treatments for patients with myelodysplastic syndromes

artículo científico publicado en 2009

Optimizing hypomethylating agents in myelodysplastic syndromes

artículo científico

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2018

Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents

artículo científico publicado en 2012

Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine

artículo científico publicado en 2013

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

artículo científico publicado en 2018

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

artículo científico publicado en 2010

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

artículo científico publicado en 2013

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).

artículo científico publicado en 2017

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis

artículo científico publicado en 2013

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.

artículo científico publicado en 2013

Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia.

artículo científico publicado en 2008

Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?

artículo científico publicado en 2020

Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie C

artículo científico publicado en 2017

Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.

artículo científico publicado en 2013

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia.

artículo científico publicado en 2012

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

artículo científico publicado en 2012

Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine

artículo científico publicado en 2012

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

artículo científico publicado en 2010

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis

artículo científico publicado en 2004

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.

artículo científico publicado en 2017

[Hypomethylating agents for the treatment of myelodysplastic syndromes]

scientific article published on 01 August 2011

Lista de obras de Raphael A Itzykson

A landscape of germline mutations in a cohort of inherited bone marrow failure patients

A multiparametric niche-like drug screening platform in acute myeloid leukemia

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease

Allogeneic hematopoietic cell transplantation following the use of hypomethylating agents among patients with relapsed or refractory AML: Findings from an international retrospective study.

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

An evolutionary perspective on chronic myelomonocytic leukemia.

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

Applying ecological and evolutionary theory to cancer: a long and winding road ⬇️

Azacitidine in untreated acute myeloid leukemia: a report on 149 patients

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia

Bleeding in patients with Budd-Chiari syndrome

CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease

CMML: Clinical and molecular aspects.

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

Choosing a hypomethylating agent in MDS: does gender matter?

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.

Clonal architecture of chronic myelomonocytic leukemias

Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy

Clonal interference of signaling mutations holds prognostic relevance in core binding factor acute myeloid leukemia.

Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML

Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation

Diagnosis of ureaplasma urealyticum septic polyarthritis by PCR assay and electrospray ionization mass spectrometry in a patient with acute lymphoblastic leukemia.

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

Epigenetics of myelodysplastic syndromes

Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

Home spirometry in bronchiolitis obliterans after allogeneic haematopoietic cell transplant.

How I treat chronic myelomonocytic leukemia

How and when to decide between epigenetic therapy and chemotherapy in patients with AML.

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases

Letter to the Editor: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.

MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.

Macrophage migration inhibitory factor is overproduced through EGR1 in TET2<sup>low</sup> resting monocytes

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study

Meeting report: myelodysplastic syndromes at ASH 2007.

Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia.

Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

Myelodysplastic syndromes

New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.

Novel M-component based biomarkers in Waldenström's macroglobulinemia

Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation.

Optimal sequencing of treatments for patients with myelodysplastic syndromes

Optimizing hypomethylating agents in myelodysplastic syndromes

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents

Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.

Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia.

Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?

Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie C

Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia.

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.

[Hypomethylating agents for the treatment of myelodysplastic syndromes]